Evidence map›Paper›PMID 39988605›Full record

ArticleNPJ vaccines2025

Molecular convergence of neutralizing antibodies in human revealed by repeated rabies vaccination.

Mizuki Fujisawa, Taishi Onodera, Daisuke Kuroda, Chidchamai Kewcharoenwong, Michihito Sasaki, Yukari Itakura, Kohei Yumoto, Arnone Nithichanon, Naoto Ito, Shinji Takeoka and 4 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mizuki FujisawaDepartment of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University (TWIns), Tokyo, Japan.
Taishi OnoderaResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan. taishi@niid.go.jp.
Daisuke KurodaResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan. dkuroda@niid.go.jp.ORCID http://orcid.org/0000-0003-2390-4785
Chidchamai KewcharoenwongDepartment of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Ching Mai, Thailand.
Michihito SasakiDivision of Molecular Pathobiology, International Institute for Zoonosis Control (IIZC), Hokkaido University, Hokkaido, Japan.ORCID http://orcid.org/0000-0003-1607-2175
Yukari ItakuraInstitute for Vaccine Research and Development, Hokkaido University, Hokkaido, Japan.
Kohei YumotoResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
Arnone NithichanonDepartment of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Naoto ItoLaboratory of Zoonotic Diseases, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan.
Shinji TakeokaDepartment of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University (TWIns), Tokyo, Japan.
Tadaki SuzukiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3820-9542
Hirofumi SawaInstitute for Vaccine Research and Development, Hokkaido University, Hokkaido, Japan.ORCID http://orcid.org/0000-0003-2569-2755
Ganjana LertmemongkolchaiDepartment of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Ching Mai, Thailand.ORCID http://orcid.org/0000-0001-6972-585X
Yoshimasa TakahashiResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan. ytakahas@niid.go.jp.

Funding

Japan Agency for Medical Research and Development (AMED) JP22fk0108141Japan Agency for Medical Research and Development (AMED) JP23gm1810004Japan Agency for Medical Research and Development (AMED) JP23wm0325047Japan Agency for Medical Research and Development (AMED) JP243fa627005Japan Agency for Medical Research and Development (AMED) JP243fa627009Japan Agency for Medical Research and Development (AMED) JP24wm0325075
6 · The paper itself

Abstract

Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neutralizing activity of recalled antibodies, primarily targeting an immunodominant site III epitope with hydrophilic and rugged structures. Strikingly, the majority of site III-directed antibodies in the recall response used a convergent V

Identifiers

PMID39988605
PMCPMC11847937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.